Companies Cryptocurrencies
Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 24/07/1991
CEO: Dr. Jeffrey Leiden
Biotechnology Healthcare 🔗
  • VRTX
  • 281.79
  • 72069488640
    market cap
  • 1.4400024
If you bought

shares of Vertex Pharmaceuticals Inc (VRTX) on
You would have made
Old Price $12 Current Price $12

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 2,500 full-time employees. The firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The firm’s marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The firm’s development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Address: 50 Northern Ave Boston MASSACHUSETTS 02210

Stay updated.